Sarepta Therapeutics Future Growth
Future criteria checks 6/6
Sarepta Therapeutics is forecast to grow earnings and revenue by 42.6% and 23.9% per annum respectively. EPS is expected to grow by 40.7% per annum. Return on equity is forecast to be 46.9% in 3 years.
Key information
42.6%
Earnings growth rate
40.7%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | 23.9% |
| Future return on equity | 46.9% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,930 | 1,520 | 1,468 | 1,786 | 13 |
| 12/31/2025 | 3,158 | 1,112 | 1,434 | 1,400 | 18 |
| 12/31/2024 | 1,794 | 214 | -287 | -56 | 18 |
| 9/30/2024 | 1,640 | 122 | -480 | -352 | N/A |
| 6/30/2024 | 1,505 | 47 | -528 | -396 | N/A |
| 3/31/2024 | 1,403 | 17 | -552 | -534 | N/A |
| 12/31/2023 | 1,243 | -536 | -486 | -501 | N/A |
| 9/30/2023 | 1,105 | -691 | -513 | -539 | N/A |
| 6/30/2023 | 1,003 | -908 | -432 | -489 | N/A |
| 3/31/2023 | 976 | -1,115 | -470 | -434 | N/A |
| 12/31/2022 | 933 | -703 | -358 | -325 | N/A |
| 9/30/2022 | 876 | -716 | -289 | -262 | N/A |
| 6/30/2022 | 835 | -507 | -348 | -322 | N/A |
| 3/31/2022 | 766 | -357 | -285 | -364 | N/A |
| 12/31/2021 | 702 | -419 | -382 | -443 | N/A |
| 9/30/2021 | 646 | -486 | -551 | -588 | N/A |
| 6/30/2021 | 600 | -634 | -681 | -702 | N/A |
| 3/31/2021 | 573 | -704 | -795 | -701 | N/A |
| 12/31/2020 | 540 | -554 | 133 | 107 | N/A |
| 9/30/2020 | 495 | -601 | 155 | 118 | N/A |
| 6/30/2020 | 450 | -530 | 342 | 289 | N/A |
| 3/31/2020 | 407 | -656 | 373 | 318 | N/A |
| 12/31/2019 | 381 | -715 | -516 | -456 | N/A |
| 9/30/2019 | 365 | -620 | -478 | -415 | N/A |
| 6/30/2019 | 345 | -570 | -536 | -461 | N/A |
| 3/31/2019 | 323 | -403 | -567 | -499 | N/A |
| 12/31/2018 | 301 | -362 | -450 | -389 | N/A |
| 9/30/2018 | 274 | -245 | -345 | -297 | N/A |
| 6/30/2018 | 241 | -216 | N/A | -242 | N/A |
| 3/31/2018 | 203 | -170 | N/A | -210 | N/A |
| 12/31/2017 | 155 | -51 | N/A | -232 | N/A |
| 9/30/2017 | 103 | -115 | N/A | -282 | N/A |
| 6/30/2017 | 57 | -124 | N/A | -285 | N/A |
| 3/31/2017 | 22 | -123 | N/A | -243 | N/A |
| 12/31/2016 | 5 | -267 | N/A | -246 | N/A |
| 9/30/2016 | 1 | -243 | N/A | -196 | N/A |
| 6/30/2016 | 1 | -239 | N/A | -182 | N/A |
| 3/31/2016 | 1 | -218 | N/A | -167 | N/A |
| 12/31/2015 | 1 | -220 | N/A | -149 | N/A |
| 9/30/2015 | 0 | -200 | N/A | -144 | N/A |
| 6/30/2015 | 1 | -177 | N/A | -133 | N/A |
| 3/31/2015 | 4 | -169 | N/A | -144 | N/A |
| 12/31/2014 | 10 | -136 | N/A | -129 | N/A |
| 9/30/2014 | 12 | -100 | N/A | -121 | N/A |
| 6/30/2014 | 15 | -113 | N/A | -105 | N/A |
| 3/31/2014 | 16 | -98 | N/A | -78 | N/A |
| 12/31/2013 | 14 | -112 | N/A | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT's forecast earnings growth (42.6% per year) is above the savings rate (2.6%).
Earnings vs Market: SRPT's earnings (42.6% per year) are forecast to grow faster than the US market (15.5% per year).
High Growth Earnings: SRPT's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SRPT's revenue (23.9% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: SRPT's revenue (23.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT's Return on Equity is forecast to be very high in 3 years time (46.9%).